BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016. BGB-3111, BGB-290 and BGB-283 are its molecularly targeted agents and is its immuno-oncology agent. BGB-3111 is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). BGB-283 is a molecule inhibitor of both the monomer and dimer forms of the RAF kinase. BGB-290 is a molecularly targeted, orally available, potent and highly selective inhibitor of the poly ADP ribose polymerase (PARP) family members. BGB-A317 is an investigational humanized monoclonal antibody against the immune checkpoint receptor, PD-1.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:BGNE
- CUSIP: N/A
- Web: www.beigene.com
Capitalization:- Market Cap: $2.79492 billion
- Outstanding Shares: 39,915,000
Average Prices:- 50 Day Moving Avg: $70.10
- 200 Day Moving Avg: $46.56
- 52 Week Range: $26.43 - $79.89
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -13.65
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $6.42 per share
- Price / Book: 10.78
Profitability:- EBIDTA: ($179,280,000.00)
- Return on Equity: -65.85%
- Return on Assets: -49.40%
Debt:- Debt-to-Equity Ratio: 0.57%
- Current Ratio: 8.38%
- Quick Ratio: 8.38%
Misc:- Average Volume: 239,406 shs.
- Beta: -0.82
- Short Ratio: 14.14
Frequently Asked Questions for BeiGene (NASDAQ:BGNE)
What is BeiGene's stock symbol?
BeiGene trades on the NASDAQ under the ticker symbol "BGNE."
How were BeiGene's earnings last quarter?
BeiGene, Ltd. (NASDAQ:BGNE) released its quarterly earnings data on Wednesday, March, 22nd. The company reported ($1.05) EPS for the quarter, missing the Zacks' consensus estimate of ($0.86) by $0.19. The company had revenue of $1 million for the quarter, compared to analyst estimates of $3.75 million. The firm's quarterly revenue was down 78.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($3.05) EPS. View BeiGene's Earnings History.
Where is BeiGene's stock going? Where will BeiGene's stock price be in 2017?
7 brokers have issued 12-month target prices for BeiGene's stock. Their forecasts range from $58.00 to $86.00. On average, they expect BeiGene's stock price to reach $76.20 in the next twelve months. View Analyst Ratings for BeiGene.
What are analysts saying about BeiGene stock?
Here are some recent quotes from research analysts about BeiGene stock:
- 1. According to Zacks Investment Research, "BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. " (8/10/2017)
- 2. Maxim Group analysts commented, "BeiGene reported 1Q17 results. The company spent $52.5M during the quarter. The increased operating expenses were driven by clinical expansion to pivotal studies. Net loss for the quarter was $50.6M or ($1.27) per share. BeiGene ended the period with $327M of liquidity on the balance sheet. We model rising R&D expenses with clinical advances." (5/11/2017)
Who are some of BeiGene's key competitors?
Some companies that are related to BeiGene include Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Clovis Oncology (CLVS), AveXis (AVXS), Juno Therapeutics (JUNO), Agios Pharmaceuticals (AGIO), Intercept Pharmaceuticals (ICPT), GW Pharmaceuticals PLC (GWPH), Ultragenyx Pharmaceutical (RARE), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Sarepta Therapeutics (SRPT), Axovant Sciences (AXON), Prothena Corporation PLC (PRTA), Loxo Oncology (LOXO), Aerie Pharmaceuticals (AERI), NovoCure Limited (NVCR) and Halozyme Therapeutics (HALO).
Who are BeiGene's key executives?
BeiGene's management team includes the folowing people:
- John V Oyler, Chairman of the Board, Chief Executive Officer, Founder
- Howard Liang Ph.D., Chief Financial Officer and Chief Strategy Officer
- Wendy Yan, Senior Vice President, Head of Regulatory Affairs
- Jason Yang M.D.Suffix is Ph.D., Senior Vice President, Head of Clinical Development
- Timothy Y. Chen, Director
- Donald W. Glazer, Director
- Michael J. Goller, Director
- Ranjeev Krishana, Director
- Xiaodong Wang Ph.D., Director
When did BeiGene IPO?
(BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.
Who owns BeiGene stock?
BeiGene's stock is owned by a variety of of retail and institutional investors. Top institutional investors include
BAKER BROS. ADVISORS LP
(23.60%), FMR LLC (10.04%), Hillhouse Capital Management Ltd. (9.32%), Artal Group S.A. (1.01%), Myriad Asset Management Ltd. (0.97%) and Ariose Capital Management Ltd (0.49%). Company insiders that own BeiGene stock include Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, John Oyler, Ruirong Yuan, Thomas Malley and Xiaodong Wang. View Institutional Ownership Trends for BeiGene.
Who sold BeiGene stock? Who is selling BeiGene stock?
BeiGene's stock was sold by a variety of institutional investors in the last quarter, including Fosun International Ltd, Conning Inc., Candriam Luxembourg S.C.A., Emory University, DAFNA Capital Management LLC, Ariose Capital Management Ltd, TD Asset Management Inc. and Airain ltd. Company insiders that have sold BeiGene stock in the last year include Donald W Glazer, John Oyler and Xiaodong Wang. View Insider Buying and Selling for BeiGene.
Who bought BeiGene stock? Who is buying BeiGene stock?
BeiGene's stock was bought by a variety of institutional investors in the last quarter, including Hillhouse Capital Management Ltd., Alliancebernstein L.P., Employees Retirement System of Texas, Myriad Asset Management Ltd., Artal Group S.A., Alps Advisors Inc., Bank of Montreal Can and NF Trinity Capital Hong Kong Ltd. Company insiders that have bought BeiGene stock in the last two years include Bros Advisors Lp Baker, Howard Liang, Ruirong Yuan and Thomas Malley. View Insider Buying and Selling for BeiGene.
How do I buy BeiGene stock?
Shares of BeiGene can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BeiGene's stock price today?
One share of BeiGene stock can currently be purchased for approximately $69.21.
MarketBeat Community Rating for BeiGene (NASDAQ BGNE)MarketBeat's community ratings are surveys of what our community members think about BeiGene and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for BeiGene (NASDAQ:BGNE) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 7 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $76.20 (10.10% upside) |
Analysts' Ratings History for BeiGene (NASDAQ:BGNE)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/15/2017 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Buy | $43.00 -> $86.00 | Low |  |
| 8/7/2017 | Ladenburg Thalmann Financial Services | Initiated Coverage | Buy -> Buy | $81.00 | High | |
| 7/10/2017 | Morgan Stanley | Reiterated Rating | Overweight | $83.00 | Medium | |
| 7/7/2017 | Maxim Group | Boost Price Target | Buy | $57.00 -> $73.00 | High | |
| 7/6/2017 | Robert W. Baird | Boost Price Target | Outperform | $44.00 -> $58.00 | High | |
| 6/1/2017 | William Blair | Reiterated Rating | Outperform | | Low | |
| 10/7/2016 | Cowen and Company | Reiterated Rating | Buy | | N/A | |
(Data available from 8/18/2015 forward)
Earnings History for BeiGene (NASDAQ:BGNE)Earnings History by Quarter for BeiGene (NASDAQ BGNE)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 3/22/2017 | Q4 | ($0.86) | ($1.05) | $3.75 million | $1.00 million | View | N/A | |
| 11/10/2016 | Q316 | ($0.78) | ($1.08) | $1.88 million | | View | N/A | |
| 8/10/2016 | Q2 | ($0.68) | ($0.73) | $2.08 million | $0.40 million | View | N/A | |
| 5/11/2016 | Q1 | ($0.05) | ($0.97) | | $0.70 million | View | N/A | |
| 3/30/2016 | Q4 | ($1.06) | ($3.05) | $1.74 million | $4.68 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for BeiGene (NASDAQ:BGNE)| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q2 2017 | 1 | ($1.20) | ($1.20) | ($1.20) |
| Q3 2017 | 1 | ($1.21) | ($1.21) | ($1.21) |
| Q4 2017 | 1 | ($1.22) | ($1.22) | ($1.22) |
(Data provided by Zacks Investment Research)
Dividend History for BeiGene (NASDAQ:BGNE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for BeiGene (NASDAQ:BGNE)Insider Ownership Percentage: 24.20%
Institutional Ownership Percentage: 43.69%
Insider Trades by Quarter for BeiGene (NASDAQ:BGNE)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/11/2017 | Bros. Advisors Lp Baker | Director | Buy | 176,056 | $71.00 | $12,499,976.00 | |
| 7/12/2017 | Xiaodong Wang | Director | Sell | 20,000 | $72.44 | $1,448,800.00 | |
| 7/10/2017 | Donald W Glazer | Director | Sell | 10,810 | $72.15 | $779,941.50 | |
| 7/6/2017 | John Oyler | CEO | Sell | 219,400 | $64.82 | $14,221,508.00 | |
| 6/28/2017 | Xiaodong Wang | Director | Sell | 35,000 | $44.95 | $1,573,250.00 | |
| 6/23/2017 | John Oyler | CEO | Sell | 98,500 | $44.16 | $4,349,760.00 | |
| 6/2/2017 | Xiaodong Wang | Director | Sell | 5,539 | $40.00 | $221,560.00 | |
| 5/4/2017 | Xiaodong Wang | Director | Sell | 14,461 | $40.80 | $590,008.80 | |
| 5/1/2017 | John Oyler | CEO | Sell | 36,149 | $40.47 | $1,462,950.03 | |
| 4/5/2017 | Xiaodong Wang | Director | Sell | 11,650 | $36.83 | $429,069.50 | |
| 3/24/2017 | Xiaodong Wang | Director | Sell | 38,107 | $36.96 | $1,408,434.72 | |
| 3/20/2017 | John Oyler | CEO | Sell | 31,989 | $39.39 | $1,260,046.71 | |
| 3/10/2017 | Xiaodong Wang | Director | Sell | 36,892 | $39.89 | $1,471,621.88 | |
| 3/6/2017 | John Oyler | CEO | Sell | 108,999 | $40.91 | $4,459,149.09 | |
| 2/27/2017 | Xiaodong Wang | Director | Sell | 38,351 | $38.19 | $1,464,624.69 | |
| 2/21/2017 | John Oyler | CEO | Sell | 64,963 | $40.55 | $2,634,249.65 | |
| 11/23/2016 | Thomas Malley | Director | Buy | 30,000 | $32.00 | $960,000.00 | |
| 11/18/2016 | Bros. Advisors Lp Baker | Director | Buy | 1,760,495 | $32.00 | $56,335,840.00 | |
| 9/28/2016 | Donald W Glazer | Director | Sell | 41,463 | $30.66 | $1,271,255.58 | |
| 9/27/2016 | Donald W Glazer | Director | Sell | 47,149 | $29.61 | $1,396,081.89 | |
| 9/23/2016 | Donald W Glazer | Director | Sell | 36,443 | $31.02 | $1,130,461.86 | |
| 9/21/2016 | Donald W Glazer | Director | Sell | 67,252 | $31.42 | $2,113,057.84 | |
| 2/8/2016 | Bros. Advisors Lp Baker | Director | Buy | 1,912,680 | $24.00 | $45,904,320.00 | |
| 2/8/2016 | Howard Liang | CFO | Buy | 65,000 | $1.85 | $120,250.00 | |
| 2/8/2016 | Ruirong Yuan | Insider | Buy | 130,000 | $1.85 | $240,500.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for BeiGene (NASDAQ:BGNE)
Latest Headlines for BeiGene (NASDAQ:BGNE)
| Source: |
|
| Date | Headline |
|---|
 | Beigene Ltd (BGNE) Rating Reiterated by Goldman Sachs Group, Inc. (The)
www.americanbankingnews.com - August 15 at 10:32 PM |
| BeiGene, Ltd. (BGNE) Director Bros. Advisors Lp Baker Purchases 176,056 Shares
www.americanbankingnews.com - August 14 at 4:30 PM |
 | BeiGene (BGNE) Prices of 2.47M Public Offering at $71/ADS
www.streetinsider.com - August 12 at 4:11 PM |
| BeiGene (BGNE) to Offer and Sell $125M ADSs
www.streetinsider.com - August 11 at 3:49 AM |
 | BeiGene Announces Pricing of $175 Million Public Offering
finance.yahoo.com - August 10 at 10:47 PM |
| BeiGene, Ltd. (BGNE) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - August 10 at 9:06 PM |
 | BeiGene Reports Second Quarter 2017 Financial Results
www.nasdaq.com - August 9 at 4:44 PM |
| BeiGene, Ltd. (BGNE) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 4 at 1:02 PM |
| BeiGene, Ltd. (BGNE) to Release Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:30 AM |
 | How WebMD Got Locked Out Of The China Market
seekingalpha.com - July 26 at 5:06 PM |
| BeiGene, Ltd. (BGNE) Director Xiaodong Wang Sells 20,000 Shares
www.americanbankingnews.com - July 13 at 7:52 PM |
| BeiGene, Ltd. (NASDAQ:BGNE) Director Donald W. Glazer Sells 10,810 Shares
www.americanbankingnews.com - July 12 at 10:50 PM |
| Comparing TESARO (TSRO) & BeiGene (NASDAQ:BGNE)
www.americanbankingnews.com - July 12 at 12:14 PM |
| BeiGene, Ltd. (NASDAQ:BGNE) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - July 11 at 9:38 PM |
| Insider Selling: BeiGene, Ltd. (BGNE) CEO Sells 219,400 Shares of Stock
www.americanbankingnews.com - July 10 at 8:12 PM |
| [$$] BeiGene Boosted by Celgene Deal
finance.yahoo.com - July 10 at 4:30 PM |
| BeiGene, Ltd. (BGNE) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 10 at 1:04 PM |
| BeiGene, Ltd. (NASDAQ:BGNE) Receives Overweight Rating from Morgan Stanley
www.americanbankingnews.com - July 10 at 10:32 AM |
 | BeiGene Ltd. (BGNE) Surged To A New High After Celgene Collaboration
www.rttnews.com - July 8 at 4:09 PM |
| BeiGene, Ltd. (BGNE) Price Target Raised to $73.00 at Maxim Group
www.americanbankingnews.com - July 8 at 11:44 AM |
| BeiGene Ltd. (BGNE) Has Climbed To A New High On Celgene Deal
www.nasdaq.com - July 6 at 4:06 PM |
| US STOCKS-Futures lower ahead of trade, ADP jobs data
finance.yahoo.com - July 6 at 4:06 PM |
| BeiGene stock surges 12% on Celgene cancer collaboration
finance.yahoo.com - July 6 at 4:06 PM |
| How Transformative Is This Licensing Deal for BeiGene?
finance.yahoo.com - July 6 at 4:06 PM |
| Biotech Movers: Immuno-Oncology Pact With Celgene Sends BeiGene Shares Soaring
finance.yahoo.com - July 6 at 4:06 PM |
| Celgene signs deal with BeiGene for tumor cancer treatment
finance.yahoo.com - July 6 at 4:06 PM |
| Here's Why BeiGene Ltd. Rose as Much as 31.4% on Thursday
finance.yahoo.com - July 6 at 4:06 PM |
| BeiGene, Ltd. (NASDAQ:BGNE) Earns Outperform Rating from Robert W. Baird
www.americanbankingnews.com - July 6 at 9:38 AM |
 | Recent CELG News
www.bloomberg.com - July 6 at 3:12 AM |
| Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with BeiGene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers
finance.yahoo.com - July 5 at 10:11 PM |
| BeiGene to Host Investor Conference Call on Global Strategic Collaboration with Celgene
finance.yahoo.com - July 5 at 10:11 PM |
| BeiGene Initiates Pivotal Trial of PD-1 Antibody BGB-A317 in China in Patients with Urothelial Cancer
finance.yahoo.com - July 5 at 5:09 PM |
| BeiGene (BGNE) Surges: Stock Moves 20.8% Higher
finance.yahoo.com - July 5 at 5:09 PM |
| This Biotech Stock Is Surging More Than 20% Today
finance.yahoo.com - July 5 at 5:09 PM |
| BeiGene, Ltd. (BGNE) PT Set at $52.00 by Maxim Group
www.americanbankingnews.com - July 3 at 5:44 PM |
| Insider Selling: BeiGene, Ltd. (BGNE) Director Sells 35,000 Shares of Stock
www.americanbankingnews.com - June 30 at 7:16 PM |
| Analysts Anticipate BeiGene, Ltd. (BGNE) Will Post Earnings of -$1.15 Per Share
www.americanbankingnews.com - June 29 at 6:30 PM |
| BeiGene Presents Preliminary Phase 1 Data on BGB-A317 in Patients with Hepatocellular Carcinoma at the ESMO 19th World Congress on Gastrointestinal Cancer
finance.yahoo.com - June 29 at 5:40 PM |
| John Oyler Sells 98,500 Shares of BeiGene, Ltd. (BGNE) Stock
www.americanbankingnews.com - June 26 at 10:40 PM |
| BeiGene Presents Initial Phase 1 Data on BTK Inhibitor BGB-3111 Combined with Obinutuzumab at the 1
www.nasdaq.com - June 16 at 4:37 PM |
| BeiGene Presents Initial Phase 1 Data on BTK Inhibitor BGB-3111 Combined with Obinutuzumab at the 14th International Conference on Malignant Lymphoma and Announces Additional Planned Global Registrational Trials for BGB-3111
finance.yahoo.com - June 16 at 4:37 PM |
| BeiGene, Ltd. (BGNE) Given a $52.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - June 15 at 11:20 PM |
| BeiGene (BGNE) Delivers Updated Phase 1 Data on BTK Inhibitor BGB-3111 in Patients with Waldenstrom’s Macroglobulinemia
www.streetinsider.com - June 15 at 10:41 PM |
| BeiGene Presents Updated Phase 1 Data on BTK Inhibitor BGB-3111 in Patients with Waldenström’s Macroglobulinemia at the 14th International Conference on Malignant Lymphoma
finance.yahoo.com - June 15 at 5:41 PM |
| BeiGene (BGNE) Announces Updated Phase 1 Data on BTK Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia & Small Lymphocytic Lymphoma
www.streetinsider.com - June 14 at 9:10 PM |
| BeiGene Presents Updated Phase 1 Data on BTK Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the 14th International Conference on Malignant Lymphoma
finance.yahoo.com - June 14 at 10:37 AM |
| BeiGene to Present Data on BGB-3111 at the 14th International Conference on Malignant Lymphoma and to Host Conference Call
finance.yahoo.com - June 7 at 4:10 PM |
| Head to Head Review: Calithera Biosciences (CALA) versus Beigene (BGNE)
www.americanbankingnews.com - June 7 at 12:51 PM |
| Beigene Ltd (BGNE) Director Xiaodong Wang Sells 5,539 Shares
www.americanbankingnews.com - June 6 at 7:51 PM |
| Brokerages Expect Beigene Ltd (BGNE) Will Post Earnings of -$1.15 Per Share
www.americanbankingnews.com - June 5 at 4:08 PM |
BeiGene (BGNE) Chart for Friday, August, 18, 2017
